Changes in Beneficial Ownership · 4
Theravance Biopharma, Inc.
Changes in Beneficial Ownership
Structured filing — 4
primary_doc.xml
Filing details
- Report period
- 2026-09-23
- Issuer
- Theravance Biopharma, Inc.
- Issuer CIK
- 0001583107
- Trading symbol
- TBPH
- No longer subject to Section 16
- Checked
Reporting owner 1
- Name
- Weiss Asset Management LP
- Reporting owner CIK
- 0001357550
- Relationship
- Other
- Other relationship
- Former 10% Owner
- Address
- 222 BERKELEY STREET, 16TH FLOOR, BOSTON, MA, 02116
Reporting owner 2
- Name
- WEISS ANDREW M
- Reporting owner CIK
- 0001357643
- Relationship
- Other
- Other relationship
- Former 10% Owner
- Address
- 222 BERKELEY STREET, 16TH FLOOR, BOSTON, MA, 02116
Reporting owner 3
- Name
- WAM GP LLC
- Reporting owner CIK
- 0001504664
- Relationship
- Other
- Other relationship
- Former 10% Owner
- Address
- 222 BERKELEY STREET, 16TH FLOOR, BOSTON, MA, 02116
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Share $0.00001 Par Value | 2026-09-23 | J · Form 4[F1] | 7,457,060[F2] | D | 17[F3] | 0 | I | See Footnote 2 |
Table key
- J · Form 4
- Other acquisition or disposition; see explanation
- D
- Disposed
- I
- Indirect
Footnotes
- F1
- On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each Ordinary Share $0.00001 Par Value of the Issuer held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.↩ 1
- F2
- Shares reported herein represent shares beneficially owned by two private investment funds for which Weiss Asset Management LP serves as investment manager. WAM GP LLC is the general partner of Weiss Asset Management LP and Andrew Weiss is the Manager of WAM GP LLC. All of Weiss Asset Management LP, WAM GP LLC, and Andrew Weiss disclaim beneficial ownership of the shares reported herein except to the extent of their pecuniary interest therein.↩ 1
- F3
- Represents the cash portion of the consideration paid to shareholders upon the closing of the Merger.↩ 1
Signature 1
- Signed
- Georgiy Nikitin, Chief Compliance Officer, Weiss Asset Management LP and WAM GP LLC
- Date
- 2026-09-28
Signature 2
- Signed
- Georgiy Nikitin, duly authorized under a power of attorney by Andrew M. Weiss
- Date
- 2026-09-28
Company context
Theravance Biopharma, Inc.’s focus is to deliver Medicines that Make a Difference® in people’s lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The Company is committed to creating/driving shareholder value.